- Clinical-stage biotech Eliem Therapeutics ( NASDAQ: ELYM ) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP).
- The primary endpoint of the 148-patient Phase 2a trial was the change in the weekly average of the daily pain score from baseline to week 4, measured using the Pain Intensity Numerical Rating Scale (PI-NRS).
- The results indicated that ETX-810 did not achieve a statistically significant separation from placebo in the primary endpoint.
- The results were similar to previously disclosed data from another Phase 2 trial in diabetic peripheral neuropathic pain (DPNP) which also indicated a lack of separation for the treatment arm compared to the placebo, the company said.
For further details see:
Eliem to discontinue development of lead asset as mid-stage pain trial fails